In 2010, there were 505,351 Canadians
|
|
- Blaze James
- 7 years ago
- Views:
Transcription
1 PRACTICAL TIPS FOR RECOGNITION AND MANAGEMENT OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA Kiran Rabheru, MD, CCFP, FRCP, geriatric psychiatrist, the Ottawa Hospital and Elizabeth Bruyere Continuing Care; associate professor, University of Ottawa, Ottawa, Ontario Correspondence may be directed to In 2010, there were 505,351 Canadians affected by Alzheimer s disease and related dementias. This number is projected to grow to 581,252 in 2015 and a staggering 1,042,113 in This translates to a new case every 5 minutes in 2008, and one every 2 minutes in 2038! The economic burden of dementia is estimated to double in every decade, increasing from $15 billion in 2008 to a startling $153 billion in Patients suffering with dementia typically experience alterations in cognition, function, and behaviour. While all three are affected, it is the behavioural domain that has proved to be the major challenge in dementia care and is experienced by over 90% of patients. 1 These behavioural and psychological symptoms of dementia (BPSD) can cause a great deal of emotional turmoil and pose a physical risk to the patient, family, and other caregivers. BPSD are known to be the most common cause of institutionalization and prolong in-hospital lengths of stay. Many retirement homes and longterm care facilities find patients with BPSD very difficult to care for as these institutions are ill equipped to care for aggressive and disruptive behaviours as their staff are inadequately trained and insufficient in numbers. Safety of other frail and vulnerable residents becomes a major issue, often leading to injuries and even death. The picture is complicated by many patients with BPSD who are incapable of making informed choices regarding the complex decisions related to their own care. This places an additional burden on scarce clinicians time as they are required to communicate and obtain informed consent from substitute decision makers (SDMs). Since extremely complex clinical issues are at play, SDMs find giving consent a very difficult process, especially when there are multiple family members with divergent opinions involved. Caregiver Attitude and Education All persons treating or caring for patients with dementia must be aware of their own attitudes and biases toward the illness and the individual patients. The quality of interaction and personal approach of the caregiver toward each patient varies tremendously, and can significantly affect how a patient responds clinically; this can reduce the need for psychotropic drug use. An appropriate level of understanding of dementia and education related to best care practices are critical for successful outcomes. Systematic Approach to BPSD A systematic approach is critical for successful outcomes in dealing with any BPSD. A SMART approach is suggested below as an aide for caregivers 2 : Safety remove patient to safe environment Medical perform an organic workup to treat reversible causes; reduce medication load Assess competency decisions regarding personal care, finances, driving; protect assets Rest, nutrition, hydration ensured; address problems with pain, ambulation, vision, hearing, constipation Trial of medication cholinesterase inhibitor/antipsychotic/antidepressant/ mood stabilizer Non-pharmacological Interventions and the Prevention of BPSD Non-pharmacological approaches and proactive recognition of the behaviour trigger(s) may often avert behavioural crises altogether. Developing simple approaches to address these early signals are the key to preventing BPSD. All patients must have non-pharmacological interventions tailored to their individual care needs for routine implementation. Look for signs of increased levels of distress, irritability, mood disturbance, and suspiciousness. Be alert for a decreased level of social activity, increased time spent in bed, a poor appetite, decreased weight, and a reversal of the sleep-wake cycle. Many BPSD are rooted in frustrations resulting from unmet needs based on social and environmental factors such as social isolation, the need for touch or intimacy, the need VOLUME 1, ISSUE 1,
2 Practical T ips for Recognition and Management of BPSD Figure 1. Non-pharmacological options for the treatment of behavioural and psychological symptoms of dementia (BPSD). for privacy during personal care, environmental noise, and temperature. Other triggers to consider include physical or verbal limitations such as the inability to verbally communicate needs or wants or to express physical or emotional distress, and the inability to move the body or a limb at will. Biological triggers to consider include difficulty with vision, hearing, the mouth or dentition, and swallowing; dehydration and malnourishment; skin problems (dryness, itching, pressure sores); bowel problems (constipation); urinary problems (infection, retention, incontinence); and feet problems (painful lesions). These factors should be routinely checked in all patients who are unable to express their own needs verbally as many serious problems can be easily prevented. Non-pharmacological interventions for BPSD are summarized below: Approach A kind, unrushed, non-confrontational, face-to-face approach may work best. Schedules Employ patient-centred care schedules. Demands Reduce demands on the patient. 18 VOLUME 1, ISSUE 1, 2011
3 Rabheru ACUTE MEDIUM LONG-TERM SAFETY ASSESS MAINTENANCE Patient, Staff, Residents 1) Rule out delirium 2) Medicate or not? 1) On what? 2) How long? Figure 2. Phases and goals of treatment of behavioural and psychological symptoms of dementia (BPSD). Apathy Aggression Aggressive resistance Physical aggression Verbal aggression Withdrawn Lack of interest Amotivation Sad Tearful Hopeless Low self-esteem Anxiety Guilt Depression Hallucinations Delusions Misidentifications Figure 3. Behavioural symptoms and clusters. Source: Adapted from McShane. 4 Walking aimlessly Pacing Trailing Restlessness Repetitive actions Dressing/undressing Sleep disturbance Agitation Psychosis Identify and document target cluster(s)/symptom(s): consider BVS Tool Rule out new medical and psychiatric causes New-onset behavioural problem = delirium until proven otherwise Implement caregiver-led non-pharmacological interventions and monitor closely Initiate pharmacological treatment if target symptom(s) sufficiently severe, persistent, disturbing, or dangerous Start appropriate initial and maintenance pharmacotherapy Monitor effects and side effects If not meeting therapeutic goals, consider switching agents, adjunctive therapy, or consult geriatric psychiatry Figure 4. Algorithm for the management of behavioural and psychological symptoms of dementia (BPSD). BVS = behavioural vital signs. Source: Adapted from Mintzer and Brawman-Mintzer. 5 Communication Communicate more effectively. Personal care Meticulous attention to good personal care is essential. Activity and environment Ensure that daytime activities and the environment are appropriate. Non-pharmacological options for the treatment of BPSD are presented in Figure 1. Three-Phase Approach to BPSD In the event of an acute behavioural crisis, safety is the first priority. This includes safety of the patient, other residents and family members, and staff involved in caring for the patient. Caregivers and front-line staff should routinely receive training for age-appropriate and dementia-specific behavioural crisis interventions. Caregivers facing an acute behavioural crisis should notify emergency services or hospital staff for prompt back-up. Temporary application of the least restrictive physical or chemical intervention may be necessary as a safety measure and to allow careful assessment of the patient. Treatment of BPSD is divided into three phases: acute, medium, and long-term (Figure 2). Behavioural Vital Signs In any acute behavioural crisis, it is important to document the patient s vital signs, including behavioural vital signs (BVS). When done accurately, BVS monitoring may give clues to the etiology of the behaviour disturbance, suggest targeted pharmacotherapy for behavioural symptoms or clusters (Figure 3), and help monitor the effectiveness of interventions over time. Please refer to the Behavioural Vital Signs Tool 3 available at the Canadian Academy of Geriatric Psychiatry website. Process of Targeting Drug Therapy for BPSD An algorithm for the management of BPSD is presented in Figure 4. A step-by-step approach should be taken: Acute Phase 1. Consider the target symptoms/clusters for drug therapy (see the BVS Tool). 2. Consider the overall behavioural frequency, severity, and impact (see BVS Tool). 3. Decide on an appropriate drug therapy for use in an acute behavioural crisis. Medium Term 4. Decide on an appropriate pharmacotherapy for medium-term use (4 6 weeks). 5. Perform a mandatory review and consider tapering the medication, if appropriate, after 4 6 weeks. Long Term 6. Carefully review whether long-term drug therapy is required (for >6 weeks). 7. Carefully document the impact of drug therapy for all phases (see the BVS Tool). VOLUME 1, ISSUE 1,
4 Practical T ips for Recognition and Management of BPSD Table 1. Suggested Treatment with Atypical Antipsychotics in Acute/Urgent Situations for BPSD Atypical Medication Usual Dosage and Formulation Usual Frequency Maximum Dose in 24 Hours Risperidone mg PO tablets, liquid, or M-tabs* q2 4h as needed and tolerated 2 mg for many dementia patients Not DLB/PDD May be higher in other conditions, e.g., schizophrenia, bipolar disorder, etc. Olanzapine mg PO tablets (Zydis) q2 4h as needed and tolerated 10 mg for dementia patients Note: IM formulation is available, but May be higher in other conditions, there is little experience with its use in e.g., schizophrenia, bipolar disorder, etc. Canada with the elderly dementia population. Dosage mg IM, max. 10 mg/24 h. Not given IV. Quetiapine mg bid 75.0 mg bid (150.0 mg tablet split = mg) BPSD = behavioural and psychological symptoms of dementia; DLB = dementia of Lewy body type; PDD = Parkinson s disease dementia. *M-tabs are rapid-dissolving tablets. Therapy for Severe Symptoms during Acute Phase The goals to accomplish during the acute phase are (1) to ensure the safety of all, (2) to allow for physical and laboratory examinations to rule out medical causes for the acute change in behaviour and (3) to provide the time and opportunity for communication between the physician, family, and other caregivers to develop a treatment plan. Considerations are as follows: Target symptoms: Limited to physical or verbal aggression, aggressive resistance, aggressive psychosis, and aggressive agitation Frequency of behaviour: Usually constant, several times a day, at least once a day but severe in each case Severity of behaviour: How difficult is it to distract or redirect the patient? Usually impossible in acute phase Impact of behaviour: Usually with significant potential for serious harm to self or others Suggested medications: Consider an antipsychotic ± benzodiazepine for a few doses only, usually one or two doses. This can be administered by mouth if the patient is compliant; give intramuscularly if non-compliant. Used to regain necessary safety for all. Recommended for acute mangement only and must not constitute medium or long-term therapy The choice of recommended agent(s) includes the following: Atypical antipsychotics: See Table 1. Patients known to have dementia of Lewy body type (DLB) or Parkinson s disease dementia (PDD) should receive quetiapine if at all possible. If other antispychotics are used, consider lowering the dose to minimize adverse effects. Typical antipsychotics: Haloperidol: mg PO tablets, liquid, or IM q2 4h as needed and tolerated. Maximum dose: 2 mg for many dementia patients; lower for patients with DLB/PDD. Loxapine: mg PO, liquid, or IM q2 4h as needed and tolerated. Maximum dose mg; lower for patients with DLB/PDD. Benzodiazepines: Lorazepam mg PO, liquid, sublingual, or IM q2 4 hours as needed and tolerated. Can be combined with haloperidol or loxapine for greater efficacy and to reduce the dose for each medication individually. Medium-Term Therapy The goal in the medium phase is to provide transitional drug therapy support for 4 6 weeks following an acute episode of BPSD. Once an acute delirium has been adequately treated medically or ruled out as a cause of BPSD, a decision must be made as to whether to continue or stop the psychotropic medication. Atypical antipsychotics do confer modest benefits in treating aggression and psychosis over 6 12 weeks (Table 2), with a number needed to treat that ranges from 5 to 14. However, they are associated with a number of major adverse outcomes and side effects, including sedation, parkinsonism, gait disturbance, dehydration, falls, chest infections, accelerated cognitive decline, stroke, and death. Therefore, they should only be continued for persistent and severe symptoms that have a major impact on safety, as described above. It is important to review the need for ongoing antipsychotic therapy after 4 6 weeks of treatment as many people with BPSD experience a significant improvement or resolution of symptoms over that period. Long-Term Management of Severe Symptoms: Beyond 6 12 Weeks The goal of long-term management is to continue treatment in order to maintain a patient s function and quality of life. This is to be done with the least effective dosage and for the shortest possible duration, while maintaining safety as well as optimal physical and mental health. Of the atypical antipsychotics, only risperidone has Health Canada approval for short-term use for aggression ± psychosis. Risperidone and olanzapine have stronger evidence base than quetiapine, but quetiapine is often chosen preferentially in patients with DLB or PDD due to an increased risk of extrapyramidal side effects in these patients. The benefit of long-term use beyond 12 weeks is not known. Longerterm trials (up to 12 months) have not shown consistent benefit. Symptoms often fluctuate and are unstable over time, particularly in the case of Alzheimer s dementia, where hallucinations tend to resolve 20 VOLUME 1, ISSUE 1, 2011
5 Rabheru Table 2. Guidelines for Maintenance Therapy of BPSD with Atypical Antipsychotics Atypical Antipsychotic Starting Dosage Usual Daily Dosage Maximum Dosage Risperidone 0.25 mg/d in very old, frail, 1 mg/d for most dementias; 2.0 mg/d for most dementias or patients with DLB or PDD not for patients with DLB or PDD not for patients with DLB or PDD Usual starting dosage is 0.5 mg/d May be given as single dose Dosages may be higher May be increased q3 5d by or divided dose, as tolerated (e.g., in schizophrenia) or lower mg/d, as tolerated (e.g., in DLB or PDD) Official indication for BPSD in Canada Olanzapine mg/d in very old, frail, 5 10 mg/d for most dementias; 10 mg/d for most dementias or patients with DLB or PDD not for patients with DLB or PDD not for patients with DLB or PDD Usual starting dosage is mg/d May be given as single dose Dosages may be higher May be increased q3 5d by or divided dose, as tolerated (e.g., in schizophrenia) or lower mg/d, as tolerated (e.g., in DLB or PDD) Quetiapine mg/d in very old, frail, 100 mg/d for most dementias; 150 mg/d some dementia or patients with DLB or PDD may be lower for patients patients need higher dosages Usual starting dosage is mg/d with DLB or PDD Wide range of dosing May be increased q3 5d by Wide range of dosing Consider first for patients with DLB mg/d, as tolerated May be given as single dose or PDD or divided dose, as tolerated Dosages may be higher (e.g., in schizophrenia) or lower (e.g., in DLB or PDD) BPSD = behavioural and psychological symptoms of dementia; DLB = dementia of Lewy body type; PDD = Parkinson s disease dementia. over a period of a few months, but delusions, aggression, and agitation may be more persistent. Therefore, long-term antipsychotic therapy beyond 6 months should only be undertaken with meticulous behavioural charting and documentation of the need for antipsychotic therapy. Careful consideration and documentation of the benefits and risks of long-term therapy are critical. Several national and international guidelines now recommend periodic attempts to taper the antipsychotic medication and monitoring for breakthrough symptoms. The choice of recommended agent(s) includes the following: For non-severe symptoms, such as agitation. These are verbal or motor activities that are repetitive and purposeless. They are often moderate in frequency, severity, and impact, with little or no risk of harm to self or others. The recommended drug class is antidepressants (see below for details). For depression and/or anxiety symptoms, antidepressants are recommended (see below for details): Risks: all associated with higher risk of falls, fractures, hyponatremia, gastrointestinal bleeding Citalopram mg PO daily Sertraline mg PO daily Venlafaxine XR mg PO daily Special point: sedating mirtazapine mg PO hs (sedating: promotes sleep, appetite, weight gain) Trazodone mg PO daily. Special point: sedating useful in divided doses for agitation and to promote sleep Other Classes of Medications and Target Symptoms for BPSD Cholinesterase Inhibitors Cholinesterase inhibitors may attenuate mood, anxiety, apathy, agitation, and psychotic symptoms if used in patients with very mild symptoms of BPSD. They are not replacements for antidepressants or antipsychotics. Recommended agents are galantamine 8 24 mg/d, donepezil 5 10 mg/d, and rivastigmine 3 9 mg/d. NMDA Glutamate Receptor Antagonist N-methyl-D-aspartate (NMDA) glutamate receptor agonists may be useful in stabilizing agitation and may have an antipsychotic sparing effect; however, they may also exacerbate the symptoms in some patients. They are usually recommended for moderate to severe Alzheimer s dementia. They are not replacements for antidepressants or antipsychotics. The recommended agent is memantine mg/d. Short-Acting Benzodiazepines Short-acting benzodiazepines must not be used for BPSD on a longterm basis. They are useful for the acute phase treatment of severe Key Points Behavioural and psychological symptoms of dementia (BPSD) are very common and have a major negative impact on patients and caregivers quality of life. A systematic approach is critical when managing BPSD ( SMART ): safety; medical; assessment of competency; rest, nutrition, hydration ensured; address problems with pain, ambulation, vision, hearing, constipation; and trial of medication. A comprehensive set of behavioural vital signs (see BVS Tool) must be monitored to systematically help recognize behavioural target symptoms and clusters of BPSD, and to monitor the effectiveness of various interventions. Non-pharmacological therapies must be an integral part of managing every patient with BPSD. Pharmacological therapy must target specific behavioural symptoms or clusters of BPSD. The therapy must be carefully monitored for efficacy and adverse effects, and be time limited. VOLUME 1, ISSUE 1,
6 Practical T ips for Recognition and Management of BPSD anxiety in patients with BPSD (see above). They may also be used for sedation prior to a specific procedure (e.g., a computed tomography scan, a catheterization, or on bath days). They are not replacements for antidepressants or antipsychotics. The recommended agent is lorazepam mg PO as needed, used sparingly. Miscellaneous Medications Valproic acid, carbamazepine, lithium, lamotrigine, gabapentin, opioids, β-blockers, and hormone therapy have insufficient evidence for use as first-line agents for treatment of BPSD. Author s Guide for Stopping Drug Use in BPSD To stop the use of antidepressants in BPSD, slowly wean or taper the drugs over 2 3 months after symptoms have been stable for 9 12 months. For cholinesterase inhibitors and memantine in BPSD, slowly wean or taper over 2 3 months when the patient has reached a stage of dementia with little or no independent function. Summary In summary, treating patients who have BPSD with sensitivity, respect, and patient-centred care may help to prevent the onset of symptoms. Once symptoms develop, many improve within 4 6 weeks of watchful waiting without the need for drugs. The physician and other caregivers must tailor a treatment plan specifically to the person s needs, with valuable input from the family. Antipsychotic drugs work for just over half of those with BPSD. They can cause side effects that can become serious if used for longer than 12 weeks. The physician must review the use of antipsychotic drugs after 6 weeks and stop the drug after 12 weeks, if possible. Patient and family input is critical at all stages of treatment decision making, where possible and appropriate. Careful observations and documentation of behavioural symptoms will clarify and simplify treatment decisions. Acknowledgements The author has done presentations for and is on the advisory boards of Pfizer, Lundbeck, and Bristol-Myers. This article has been peer reviewed. References 1. Alzheimer Society of Canada. Rising Tide: The Impact of Dementia on Canadian Society. Toronto (ON): The Society; Rabheru K. Take a S-M-A-R-T approach: unpredictable course of dementia symptoms can be managed. Can Fam Physician2003;49: Rabheru K. Behavioral Vital Signs Tool. Toronto (ON): Canadian Academy of Geriatric Psychiatry; Documents/Module%202%20-%20BVS%20Tool.pdf. Accessed December 19, McShane RH. What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychogeriatr 2000;12 Suppl 1: Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry 1996;57 Suppl 7: Bibliography De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5): Ellison M. Agitation in dementia: update and prospectus. Psych Times 2008;25(2):1 2. Guidelines and Protocols Advisory Committee. BC Provincial Dementia Guidelines for Family Physicians. Victoria (BC): BC Ministry of Health, 2007; cognitive.pdf. Accessed December 19, Mittal V, Kurup L, Williamson D, et al. Review: risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 2011;26: Passmore MJ, Gardner D, Polak Y, Rabheru K. Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs Aging 2008;25(5): Patterson CJS, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160(12 Suppl):s1 15. Rabheru K. Depression in dementia: diagnosis and treatment. Psych Times 2004;21(13):1 2. Schuyler D. Recognition of apathy as marker for dementia growing. Psych Times 2007;3(10):1 3. Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia; Official Website, 2007; Accessed December 19, VOLUME 1, ISSUE 1, 2011
Emergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationAntipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers
SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this
More informationClinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationDementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationPrimary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationAntipsychotics in people with dementia an update and reminder
www.bpac.org.nz keyword: dementia Antipsychotics in people with dementia an update and reminder Key concepts: Non-pharmacological treatments for the behavioural and psychological symptoms of dementia (BPSD)
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA
ASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA Overview: Psychosis is a common clinical feature of dementia. Hallucinations and delusions are the two most common types of psychotic symptoms
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationadaptations whenever possible, to prevent or reduce the occurrence of challenging behaviours.
POSITION STATEMENT on Management of Challenging Behaviours in People with Dementia 1. AIM OF THE POSITION STATEMENT This position statement applies to people living in supported accommodation and those
More informationMANAGEMENT OF DIFFICULT BEHAVIORS IN DEMENTIA
MANAGEMENT OF DIFFICULT BEHAVIORS IN DEMENTIA Danielle Hansen, DO, MS (Med Ed), MHSA Objectives Understand the prevalence of Behavioral and Psychological Symptoms of Dementia (BPSD) among individuals with
More informationPharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence
Pharmacotherapy of BPSD Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Pharmacological interventions Reducing medication errors. Reducing potentially inappropriate medication prescription.
More informationPresently, there are no means of preventing bipolar disorder. However, there are ways of preventing future episodes: 1
What is bipolar disorder? There are two main types of bipolar illness: bipolar I and bipolar II. In bipolar I, the symptoms include at least one lifetime episode of mania a period of unusually elevated
More informationPharmacological Management of Neuropsychiatric Symptoms of Dementia
Pharmacological Management of Neuropsychiatric Symptoms of Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor and Clinician Scientist, Department of Psychiatry Queen s University Department of Psychiatry
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationDepression in the Elderly: Recognition, Diagnosis, and Treatment
Depression in the Elderly: Recognition, Diagnosis, and Treatment LOUIS A. CANCELLARO, PhD, MD, EFAC Psych Professor Emeritus and Interim Chair ETSU Department of Psychiatry & Behavioral Sciences Diagnosis
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationCOMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA
COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA Manic depressive illness is a biological brain disorder that produces significant alterations of mood and psychosis. Mania in the elderly occurs
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationMOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
More informationChapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
More informationCorporate Presentation May 13, 2015
Corporate Presentation May 13, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationAn Introduction to Lewy Body Dementia
An Introduction to Lewy Body Dementia A special publication for people newly diagnosed with Lewy body dementia and those still seeking answers. You don t have to face LBD alone. Increasing Knowledge Sharing
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationBIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS
BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical
More informationDementia & Movement Disorders
Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia
More informationSexual Behavior in Dementia
Sexual Behavior in Dementia Paul Mulhausen, MD 2014 Disclosure I have no conflict of interest to report None of the medication treatments discussed in this presentation have an FDA-approved indication
More informationObjectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment
Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More information`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå. aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí=
`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí= Overview: Common Mental What are they? Disorders Why are they important? How do they affect
More informationCare Manager Resources: Common Questions & Answers about Treatments for Depression
Care Manager Resources: Common Questions & Answers about Treatments for Depression Questions about Medications 1. How do antidepressants work? Antidepressants help restore the correct balance of certain
More informationUpdate of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012
Update of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 1) New recommendation for the management of Alzheimer s disease
More informationLewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
More informationNew Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
More informationGuidelines for Dementia Syndrome
Guidelines for Dementia Syndrome Dementia is the chronic acquired decline in memory and at least one other cognitive function (e.g. language, visual-spatial, executive) sufficient to offset daily life.
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More information2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationPsychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome
Dr. May Lam Assistant Professor, Department of Psychiatry, The University of Hong Kong Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome a mental state in
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationSymptoms of mania can include: 3
Bipolar Disorder This factsheet gives information on bipolar disorder. It explains the symptoms of bipolar disorder, treatments and ways to manage symptoms. It also covers what treatment the National Institute
More informationA BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES
INTRODUCTION A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications.
More informationManaging depression after stroke. Presented by Maree Hackett
Managing depression after stroke Presented by Maree Hackett After stroke Physical changes We can see these Depression Emotionalism Anxiety Confusion Communication problems What is depression? Category
More informationDisclosure Statement. Nursing Facility Regulations and Psychotropic Medication Use. Learning Objectives (Cont) Learning Objectives
Nursing Facility Regulations and Psychotropic Medication Use Jeffrey C. Reist PharmD, BCPS College of Pharmacy The University of Iowa December 2010 Disclosure Statement I, Jeffrey Reist, PharmD, BCPS do
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationFACT SHEET 4. Bipolar Disorder. What Is Bipolar Disorder?
FACT SHEET 4 What Is? Bipolar disorder, also known as manic depression, affects about 1 percent of the general population. Bipolar disorder is a psychiatric disorder that causes extreme mood swings that
More informationManagement of Alzheimers Disease and Related Dementias
Management of Alzheimers Disease and Related Dementias Guidelines Being Compared: 1. American College of Physicians/American Academy of Family Physicians (ACP/AAFP). Current pharmacologic treatment of
More informationThis document presents the recommendations of an
SPECIAL ARTICLES Consensus Statement on Improving the Quality of Mental Health Care in U.S. Nursing Homes: Management of Depression and Behavioral Symptoms Associated with Dementia American Geriatrics
More informationAssisted Living Nurse Competencies
Assisted Living Nurse Competencies Competencies Necessary for Nurses to Provide High-Quality Care to Older Adults in Assisted Living Residences 1. Recognize one s own and others attitudes, values, and
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More informationWhat is Bipolar Disorder?
What is Bipolar Disorder? We all get excited by new ideas, pursue our goals with passion, have times when we want to party with our friends and enjoy life to its fullest. There will also be times when
More informationDementia End-of-Life Care
Dementia End-of-Life Care Dr. L. Badenhorst Riverview Health Centre Behaviour Management Chronic Care End-of-Life Care in Dementia Definitions Dementia Palliative Care End-of-Life care Challenges Diagnosing
More informationSee also www.thiswayup.org.au/clinic for an online treatment course.
Depression What is depression? Depression is one of the common human emotional states. It is common to experience feelings of sadness and tiredness in response to life events, such as losses or disappointments.
More informationDementia with Lewy bodies
IS 18 April 2011 Information sheet Dementia with Lewy bodies Introduction... 1 Key points... 1 What is dementia with Lewy bodies?... 1 How many people are affected by DLB?.. 2 What is the cause?... 2 Symptoms...
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More informationWashington State Regional Support Network (RSN)
Access to Care Standards 11/25/03 Eligibility Requirements for Authorization of Services for Medicaid Adults & Medicaid Older Adults Please note: The following standards reflect the most restrictive authorization
More informationo DOSAGE AND ADMINISTRATION Dosage in Special Populations: The recommended initial dose is 0.5 mg BID in patients who are elderly
Some critics of Janssen, including plaintiff s lawyers, have stated it is improper for Risperdal to have been used to treat elderly dementia patients. As you consider that position, we suggest you consider
More informationPatients with dementia and other types of structural brain injury are predisposed to delirium (i.e., abrupt onset, temporary confusion caused by
Dementia is the permanent loss of multiple intellectual functions resulting from neuronal death. Dementia afflicts 10% of individuals over the age of 65 and these patients survive approximately seven years
More informationSteps to getting a diagnosis: Finding out if it s Alzheimer s Disease.
Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Memory loss and changes in mood and behavior are some signs that you or a family member may have Alzheimer s disease. If you have
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationThe number of seniors receiving
Use of Psychotropics in Long-term Care Facilities for the Elderly Psychotropic medications are frequently prescribed in long-term care facilities for the elderly, despite the fact that a number of factors
More informationDepression is a medical illness that causes a persistent feeling of sadness and loss of interest. Depression can cause physical symptoms, too.
The Family Library DEPRESSION What is depression? Depression is a medical illness that causes a persistent feeling of sadness and loss of interest. Depression can cause physical symptoms, too. Also called
More informationRecommended Geropsychiatric Competency Enhancements for Nurse Practitioners Who Provide Care to Older Adults but are not Geriatric Specialists
Recommended Geropsychiatric Competency Enhancements for Nurse Practitioners Who Provide Care to Older Adults but are not Geriatric Specialists These recommended competency enhancement statements are not
More informationin young people Management of depression in primary care Key recommendations: 1 Management
Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based
More informationDelirium. The signs of delirium are managed by treating the underlying cause of the medical condition causing the delirium.
Delirium Introduction Delirium is a complex symptom where a person becomes confused and shows significant changes in behavior and mental state. Signs of delirium include problems with attention and awareness,
More informationMental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca
Mental health issues in the elderly January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca Cognitive Disorders Outline Dementia (294.xx) Dementia of the Alzheimer's Type (early and late
More informationHow To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
More informationDonepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease
IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect
More informationDepression & Multiple Sclerosis
Depression & Multiple Sclerosis Managing specific issues Aaron, diagnosed in 1995. The words depressed and depression are used so casually in everyday conversation that their meaning has become murky.
More informationProgression MIDDLE STAGE. What is Alzheimer s disease?
Progression MIDDLE STAGE This document is one in a five-part series on the stages of Alzheimer s disease and is written for the person with the disease, their family and caregivers. The middle stage of
More informationStandardised care process (SCP): depression
Standardised care process (SCP): depression Topic Identifying and responding to symptoms of depression Objective To promote evidence-based practice in how staff identify and respond to symptoms of depression
More informationDepression & Multiple Sclerosis. Managing Specific Issues
Depression & Multiple Sclerosis Managing Specific Issues Feeling blue The words depressed and depression are used so casually in everyday conversation that their meaning has become murky. True depression
More informationGeriatric Mood and Anxiety Disorders: 5 Things you need to know about Treating Depression in the Elderly
Geriatric Mood and Anxiety Disorders: 5 Things you need to know about Treating Depression in the Elderly Kiran Rabheru MD, CCFP, FRCP Geriatric Psychiatrist, The Ottawa Hospital Professor, University of
More informationMajor Depression. What is major depression?
Major Depression What is major depression? Major depression is a serious medical illness affecting 9.9 million American adults, or approximately 5 percent of the adult population in a given year. Unlike
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationDepre r s e sio i n o i n i a dults Yousuf Al Farsi
Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis
More informationUnderstanding Antipsychotic Medications
Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 1.1
More informationAUTISM SPECTRUM DISORDERS
AUTISM SPECTRUM DISORDERS JAGWINDER SANDHU, MD CHILD, ADOLESCENT AND ADULT PSYCHIATRIST 194 N HARRISON STREET PRINCETON, NJ 08540 PH: 609 751 6607 Staff Psychiatrist Carrier clinic Belle Mead NJ What is
More informationHow To Write Long Term Care Insurance
By Lori Boyce, AVP Risk Management and R&D Underwriting long term care insurance: a primer Every day Canadians die, are diagnosed with cancer, have heart attacks and become disabled and our insurance solutions
More informationFeeling Moody? Major Depressive. Disorder. Is it just a bad mood or is it a disorder? Mood Disorders. www.seclairer.com S Eclairer 724-468-3999
Feeling Moody? Is it just a bad mood or is it a disorder? Major Depressive Disorder Prevalence: 7%; 18-29 years old; Female>Male DDx: Manic episodes with irritable mood or mixed episodes, mood disorder
More informationFax # s for CAMH programs and services
INFORMATION AND INSTRUCTIONS STEP 1 BEFORE COMPLETING THE REFERRAL FORM CATS Program / General Psychiatry Memory Clinic, Geriatric Mental Health Program Go to www.camh.net for detailed information on each
More informationPostpartum Depression and Post-Traumatic Stress Disorder
Postpartum Depression and Post-Traumatic Stress Disorder Emotional Recovery: Postpartum Depression and Post-Traumatic Stress Disorder By: Lisa Houchins Published: July 23, 2013 Emotions vary widely after
More informationWho We Serve Adults with severe and persistent mental illnesses such as schizophrenia, bipolar disorder and major depression.
We Serve Adults with severe and persistent mental illnesses such as schizophrenia, bipolar disorder and major depression. We Do Provide a comprehensive individually tailored group treatment program in
More information